A month has gone by since the last earnings report for GitLab Inc. (GTLB) . Shares have added about 7% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Gitlab due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for GitLab Inc. before we dive into how investors and analysts have reacted as of late.Gitl ...

It has been about a month since the last earnings report for Macy's (M) . Shares have added about 5.5% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Macy's due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Macy's, Inc. before we dive into how investors and analysts have reacted as of lat ...

Core Viewpoint - Box's recent earnings report shows a mixed performance with a decline in earnings year over year, but revenues have increased, indicating potential growth opportunities despite recent stock underperformance [1][2]. Financial Performance - Box reported Q2 fiscal 2026 non-GAAP earnings of 33 cents per share, a 25% decline year over year, but exceeded the Zacks Consensus Estimate by 6.45% [2]. - Total revenues reached $294 million, surpassing the consensus mark by 1.21%, with a 9% year-over-year increase on a reported basis and 7% on a constant-currency basis [2]. - Billings for the quarter were $265 million, reflecting a 3.3% year-over-year increase on a reported basis and 6% on a constant-currency basis [3]. - The company's net retention rate improved to 103%, up 100 basis points year over year [3]. Remaining Performance Obligations - Box's remaining performance obligations (RPO) totaled $1.5 billion, marking a 16% year-over-year increase on both reported and constant-currency bases [4]. - Short-term RPO was $812 million (up 12% year over year), while long-term RPO was $664 million (up 21% year over year) [4]. Operating Metrics - The non-GAAP gross margin for Q2 was 81%, contracting by 20 basis points year over year but expanding by 100 basis points sequentially [5]. - The non-GAAP operating margin was 28.6%, which expanded by 20 basis points year over year and 400 basis points sequentially [5]. Cash Flow and Share Repurchase - As of July 31, 2025, cash and cash equivalents were $758 million, an increase from $689.7 million as of April 30, 2025 [6]. - Box generated $46 million in cash from operations in Q2, down from $127.1 million in the previous quarter, and recorded a non-GAAP free cash flow of $35.7 million [6]. - The company repurchased approximately 1.2 million shares for $40 million, with about $112 million remaining under its current buyback capacity [7]. Guidance - For Q3 fiscal 2026, Box expects revenues between $298 million and $299 million, indicating an 8% year-over-year increase [8]. - For fiscal 2026, Box anticipates revenues between $1.16 billion and $1.175 billion, also reflecting an 8% year-over-year increase [9]. Market Position and Estimates - Since the earnings release, there has been a downward trend in estimates, with the consensus estimate shifting by 197.06% [10]. - Box has a subpar Growth Score of D, but a strong Momentum Score of A, resulting in an aggregate VGM Score of D [11]. - The stock holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [12]. Industry Comparison - Box operates within the Zacks Internet - Software industry, where competitor Zoom Communications has seen a 2.5% gain over the past month, reporting revenues of $1.22 billion with a year-over-year change of +4.7% [13]. - Zoom's expected earnings for the current quarter indicate a +2.9% change from the year-ago quarter, with a Zacks Rank 1 (Strong Buy) [14].

Company Overview - Kodiak Sciences Inc. reported a loss of $1.03 per share in Q2 2025, which was wider than the Zacks Consensus Estimate of a loss of $1.01, and compared to a loss of $0.86 per share in the same quarter last year [2] - The company currently has no approved products and has not generated any revenues [2] Financial Performance - Research and development expenses for the reported quarter were $42.8 million, reflecting a 32% increase year-over-year due to heightened clinical activities [3] - General and administrative expenses decreased to $12.8 million, down 18% year-over-year, primarily due to lower non-cash stock-based compensation expenses [3] - As of June 30, 2025, Kodiak had cash, cash equivalents, and marketable securities totaling $104.2 million, down from $138.9 million as of March 31, 2025, which the company believes is sufficient to support operations into 2026 [4] Market Sentiment - There has been a downward trend in estimates for Kodiak Sciences, with the consensus estimate shifting down by 14.44% over the past month [5] - The stock has a Growth Score of B but is rated F for Momentum and D for Value, resulting in an aggregate VGM Score of F [6] Industry Comparison - Kodiak Sciences is part of the Zacks Medical - Biomedical and Genetics industry, where Exact Sciences (EXAS) has seen a 24.5% gain over the past month, reporting revenues of $811.09 million for the last quarter, a 16% year-over-year increase [8] - Exact Sciences is expected to post earnings of $0.10 per share for the current quarter, indicating a 147.6% change from the year-ago quarter, with a Zacks Rank of 3 (Hold) [9]

Core Insights - Brinker International reported strong fourth-quarter fiscal 2025 results, with both earnings and revenues surpassing estimates and showing year-over-year growth [3][6] - Chili's performance was a significant driver, with same-store sales increasing by 24%, outperforming the casual dining sector [4][9] - Maggiano's faced challenges with a leadership change and declining sales, indicating potential areas for improvement [5][10] Financial Performance - Adjusted earnings per share (EPS) for Q4 were $2.49, exceeding the Zacks Consensus Estimate of $2.43, compared to $1.61 in the prior year [6] - Total revenues reached $1,461.9 million, beating the consensus mark of $1,411 million, and reflecting a 21% increase year-over-year [6] - Chili's segment revenues rose 24% year-over-year to $1,339.6 million, driven by increased foot traffic and effective marketing strategies [7] Segment Analysis - Chili's same-store sales increased by 23.7%, with company-owned traffic gaining 16.3% year-over-year [9] - Maggiano's revenues decreased by 1.2% year-over-year to $122.3 million, primarily due to poor comparable restaurant sales [10] - Maggiano's company restaurant expenses as a percentage of sales rose to 86.7%, impacted by an unfavorable menu item mix [12] Operating Results - Total operating costs and expenses for the quarter were $1.32 billion, up from $1.14 billion in the previous year [13] - Adjusted restaurant operating margin improved to 17.8% from 15.2% year-over-year [13] - Adjusted EBITDA for Q4 was $212.4 million, compared to $141.8 million in the prior year [13] Balance Sheet - As of June 25, 2025, cash and cash equivalents were $64.6 million, up from $15.1 million a year earlier [14] - Long-term debt decreased to $426 million from $786.3 million year-over-year [14] Future Outlook - For fiscal 2026, management anticipates total revenues between $5.60 billion and $5.70 billion, with adjusted diluted EPS projected in the range of $9.90 to $10.50 [15] - Recent estimates have trended upward, with a consensus estimate shift of 10.83% [16] - Brinker International holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [18]

Company Overview - Theravance Biopharma's shares have increased by approximately 9.8% since the last earnings report, outperforming the S&P 500 [1] - The company reported a narrower than expected adjusted net loss of 8 cents per share for Q2 2025, compared to the Zacks Consensus Estimate of a loss of 14 cents [3] - Total revenues for Q2 2025 reached $26.2 million, significantly exceeding the Zacks Consensus Estimate of $17 million, and representing an 83.2% year-over-year increase [4] Revenue Breakdown - The revenue growth was driven by increased collaboration revenues from partner Viatris and licensing revenues [4] - Collaboration revenues from Viatris related to Yupelri sales amounted to $18.7 million, reflecting a 31% year-over-year increase [5] - Theravance received a milestone payment of $7.5 million from Viatris following the approval of Yupelri in China [5] Expense Analysis - Research and development expenses (excluding share-based compensation) totaled $9.5 million, an increase of nearly 8% from the previous year [6] - Selling, general and administrative expenses (excluding share-based compensation) rose approximately 16.4% year-over-year to $12.8 million [6] - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities worth $338.8 million, up from $130.9 million as of March 31, 2025 [6] Financial Guidance - Theravance reaffirmed its financial guidance for 2025, expecting adjusted R&D expenses in the range of $32-$38 million and adjusted SG&A expenses between $50 million and $60 million [7] - The company anticipates share-based compensation expenses of $18-$20 million in 2025 and expects adjusted losses and cash burn to be similar to 2024 levels [7] Market Sentiment - There has been a positive trend in fresh estimates, with the consensus estimate shifting by 36.84% recently [8] - Theravance holds a Growth Score of A but has a lower Momentum Score of C, with an overall VGM Score of A [10] - The stock has a Zacks Rank of 3 (Hold), indicating an expectation of an in-line return in the coming months [11] Industry Comparison - Theravance operates within the Zacks Medical - Drugs industry, where another player, United Therapeutics, has seen a 28% gain over the past month [12] - United Therapeutics reported revenues of $798.6 million for the last quarter, reflecting an 11.7% year-over-year increase, with an EPS of $6.41 compared to $5.85 a year ago [12]

Company Overview - Mercury Systems reported adjusted earnings of 47 cents per share for Q4 fiscal 2025, beating the Zacks Consensus Estimate by 123.81% and increasing 104.3% year-over-year from 23 cents per share in the prior year quarter [2][5] - Revenues for Q4 fiscal 2025 were $273.1 million, reflecting a 9.9% year-over-year increase and surpassing the Zacks Consensus Estimate by 12.99% [3][4] - Total bookings for Q4 fiscal 2025 were $341.5 million, resulting in a book-to-bill ratio of 1.25 [4] Financial Performance - Adjusted EBITDA for Q4 fiscal 2025 was $51.3 million, compared to $31.2 million for Q4 fiscal 2024, with an adjusted EBITDA margin of 18.8%, an improvement of 620 basis points year-over-year [5] - GAAP net income for Q4 fiscal 2025 was $16.4 million, with diluted earnings per share of $0.27, compared to a GAAP net loss of $10.8 million and a loss per share of $0.19 in Q4 fiscal 2024 [5] Balance Sheet & Cash Flow - As of June 27, 2025, cash and cash equivalents totaled $309.1 million, up from $269.8 million as of March 28, 2025, while long-term debt remained unchanged at $591.5 million [6] - Cash flow from operations was $38.1 million in the reported quarter, down from $71.8 million in the prior year quarter, with free cash flow at $34.0 million compared to $61.4 million for Q4 fiscal 2024 [6] Future Guidance - The company expects low single-digit revenue growth for fiscal 2026, with the first half remaining relatively flat year-over-year and sequential volume increases in the second half [7] - Adjusted EBITDA margin is projected to approach mid-teens for fiscal 2026, starting with low double-digit margins in the first half and expanding through the year [7] Market Position - Mercury Systems has a Zacks Rank 3 (Hold), indicating an expectation of an in-line return from the stock in the coming months [11] - The stock has a Growth Score of A but lags in Momentum Score with a D, and a Value Score of D, placing it in the bottom 40% for value investors [10]

Core Viewpoint - Vornado's recent earnings report indicates a mixed performance, with a slight increase in share price but a decline in year-over-year financial metrics, raising questions about future performance leading up to the next earnings release [1][14]. Financial Performance - Vornado's Q2 2025 FFO was 56 cents per share, exceeding the Zacks Consensus Estimate of 53 cents, but down 1.8% year-over-year [2]. - Total revenues for the quarter were $441.4 million, missing the Zacks Consensus Estimate of $455.4 million, and reflecting a nearly 2% decrease year-over-year [3]. Same-Store NOI - Total same-store NOI for the quarter was $260.8 million, an increase from $247.4 million in the prior-year quarter, with notable growth in specific portfolios: New York (1.8%), THE MART (57.7%), and 555 California Street (3.1%) [4]. Leasing Activity - In the New York office portfolio, 1.5 million square feet were leased at an initial rent of $101.44 per square foot, with a weighted average lease term of 6.8 years [5]. - The New York retail portfolio saw 57,000 square feet leased at an initial rent of $96.77 per square foot, with a weighted average lease term of 8.1 years [6]. - At THE MART, 127,000 square feet were leased at an initial rent of $50.87 per square foot, with a weighted average lease term of 5.6 years [7]. Occupancy Rates - The total occupancy in the New York portfolio was 85.2%, down 310 basis points year-over-year, while THE MART's occupancy was 78.2%, up 130 basis points year-over-year, and 555 California Street's occupancy was 92.3%, down 220 basis points year-over-year [8]. Portfolio Activity - A joint venture, in which Vornado holds a 50% interest, completed the sale of the 49 West 57th Street commercial condominium for $8.7 million during the quarter [9]. Balance Sheet - Vornado ended Q2 2025 with cash and cash equivalents of $1.2 billion, a significant increase from $568.9 million as of March 31, 2025 [10]. Market Outlook - There has been an upward trend in estimates revision for Vornado, indicating a potentially positive outlook [11][14]. - Vornado holds a Zacks Rank 3 (Hold), suggesting an expectation of an in-line return in the coming months [14]. Industry Comparison - Vornado operates within the Zacks REIT and Equity Trust - Other industry, where Alexandria Real Estate Equities has gained 3.5% over the past month, despite reporting a year-over-year revenue decline of 0.6% [15][16].

Core Viewpoint - Waters Corporation reported strong second-quarter earnings, surpassing estimates and showing year-over-year growth in both earnings and revenue, indicating positive momentum leading into the next earnings release [2][9]. Financial Performance - Non-GAAP earnings for Q2 2025 were $2.95 per share, exceeding the Zacks Consensus Estimate by 0.68% and reflecting a 12% increase year-over-year [2]. - Net sales reached $771.33 million, surpassing estimates by 3.63%, with a 9% increase on a reported basis and 8% on a constant currency basis year-over-year [2]. - The adjusted operating margin was 29.1%, a slight contraction of 10 basis points year-over-year [7]. Segment Performance - The Waters segment accounted for 89.3% of net sales, generating $688.8 million, up 11% year-over-year [3]. - Instruments sales (40% of net sales) were $308.4 million, increasing 5% year-over-year, while Services (38.6% of net sales) saw sales of $297.9 million, climbing 9% [4]. - Chemistry sales (21.4% of net sales) grew 17% year-over-year to $165 million [4]. Market Breakdown - The Pharmaceutical market, representing 59.9% of net sales, generated $462 million, up 11% year-over-year [5]. - The Industrial market (30.8% of net sales) reported sales of $237.7 million, a 7.3% increase year-over-year [5]. - The Academic & Government market (9.3% of net sales) remained flat year-over-year at $71.7 million [5]. Geographic Performance - Asia accounted for 34.5% of net sales with $265.9 million, up 12% year-over-year [6]. - Sales in the Americas (36.4% of net sales) were $280.7 million, increasing 2% year-over-year [6]. - Europe (29.1% of net sales) generated $224.6 million, reflecting a 14% year-over-year increase [6]. Guidance and Outlook - For Q3 2025, Waters expects non-GAAP earnings of $3.15-$3.25 per share, indicating year-over-year growth of approximately 8% to 11% [9]. - For the full year 2025, non-GAAP earnings are anticipated to be between $12.95 and $13.05 per share, reflecting a year-over-year growth of approximately 9% to 10% [10]. - Total sales growth for 2025 is projected to be in the range of 5% to 7% [10].

Core Viewpoint - Allegiant Travel's recent earnings report shows a mixed performance, with a significant earnings beat but a decline in year-over-year earnings, raising questions about future performance as the stock has outperformed the S&P 500 by 32% in the past month [1][2]. Financial Performance - Allegiant reported Q2 2025 earnings of $1.23 per share, exceeding the Zacks Consensus Estimate of 83 cents, but down 30.5% from the previous year [2]. - Operating revenues reached $689.4 million, slightly below the consensus estimate of $698.4 million, but up 3.5% year-over-year [2]. - Passenger revenues, which made up 89.6% of total revenues, increased by 3.9% year-over-year [3]. Operational Metrics - Air traffic, measured in revenue passenger miles, grew by 12% year-over-year, while capacity, measured in available seat miles (ASMs), increased by 16.1% [3]. - The load factor decreased to 81.9% from 84.7%, indicating that traffic did not keep pace with capacity growth [3]. - Operating costs per available seat mile, excluding fuel, fell by 2.5% year-over-year to 8.29 cents [4]. Cost and Revenue Insights - The average fuel cost per gallon decreased by 22.2% year-over-year to $2.49 [4]. - Total scheduled service passenger revenue per available seat mile fell to 13.01 cents from 13.16 cents a year ago [4]. Liquidity and Debt - As of June 30, 2025, Allegiant's total unrestricted cash and investments were $852.7 million, down from $906.3 million in the previous quarter [6]. - Long-term debt and finance lease obligations totaled $1.77 billion, slightly up from $1.74 billion in the prior quarter [6]. Future Guidance - For Q3 2025, scheduled service ASMs are expected to increase by 10% year-over-year, with adjusted loss per share anticipated in the range of $1.25 to $2.25 [7]. - For the full year 2025, scheduled service ASMs are projected to rise by 13%, with adjusted EPS expected to exceed $3.25 [8]. Industry Comparison - Allegiant Travel is part of the Zacks Transportation - Airline industry, where competitor SkyWest reported a revenue increase of 19.4% year-over-year, with an EPS of $2.91 [13]. - SkyWest's consensus estimate for the current quarter is $2.56 per share, reflecting an 18.5% year-over-year change [14].